Verition Fund Management
JNCE

Verition Fund Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Verition Fund Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-172,772
Closed -$1.21M – 1837
2020
Q4 		$1.21M Buy
172,772
+82,317
+91% +$641K 0.01% 476
2020
Q3 		$738K Buy
+90,455
New +$561K 0.01% 452
2020
Q2 		– Sell
-146,612
Closed -$696K – 1193
2020
Q1 		$696K Buy
+146,612
New +$844K 0.03% 284

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Verition Fund Management's JNCE Position: Q1 2021 in Review

Verition Fund Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 172,772 shares — an estimated $1.21M sold.

Verition Fund Management first reported a position in JNCE in Q1 2020 and held it in 3 quarters. The position peaked at $1.21M in Q4 2020. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

  • Verition Fund Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Verition Fund Management sold 172,772 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.21M.
  • Verition Fund Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Verition Fund Management's Jounce Therapeutics, Inc. Common Stock position peaked at $1.21M in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Verition Fund Management's 13F filing for Q1 2021, filed 18 May 2021.